US 11111306
IL-7R-alpha specific antibodies for treating acute lymphoblastic leukemia
granted A61KA61K2039/505A61K31/395
Quick answer
US patent 11111306 (IL-7R-alpha specific antibodies for treating acute lymphoblastic leukemia) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Sep 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The United States of America, as represented by the Secretary, Department of Health and Human Services
- Grant date
- Tue Sep 07 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Sep 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 31
- CPC classes
- A61K, A61K2039/505, A61K31/395, A61K39/3955, A61K39/39558